reports
- GlobalData Healthcare Department
Protalix BioTherapeutics Inc (PLX) - Financial Analysis Review
Summary Protalix BioTherapeutics Inc (PLX) - Financial Analysis Review Summary Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s pipeline products include PRX-102, a therapeutic enzyme for the treatment of Fabry disease; PRX-110, a plant cell-expressed recombinant form of human deoxyribonuclease I and is intended for the treatment of cystic fibrosis. Its PRX-106 is an orally delivered anti ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.